ALVIMOPAN
BRAND NAME:-Enterg,
ALVIMOPAN is a drug which behave as a peripherally acting u- opioid respestor antagonist for the treatment of postoperative ileus and constipation following abdominal surgery.
It is currently approved in May 2008 by food and drugs administration.
MECHANISM OF ACTION:-
Alvimopan absorption from gout and its penetration into brain is poor due to its polar nature. Administered orally before and after surgery,it hastened of bowel function.
Alvimopan competitively binds to mu-opioid receptor in the gastrointestinal tract but, unlike methylnaltrexone which relies upon it ionic charge, alvimopan owes its selectivity for peripheral receptors to its pharmacokinetics. Alvimopan binds to peripheral mu-receptors with a Ki of 0.2 ng/mL.
USE:-treatment of postoperative ileus and constipation following abdominal surgery.
SIDE EFFECTS:- Potential risk myocardial infarction in patients used in long trem, & some other back pain, Hypokalaemia etc.
DOSE:-Alvimopan is only approved for short term use of no more than 15 doses.
Comments
Post a Comment